SCOTTSDALE, Ariz., May 2, 2012 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a provider of oncology-based diagnostic tests and clinical laboratory services to the pharmaceutical and biotechnology industries, is pleased to announce the opening of its new 13,611 sq. ft. laboratory. The newly remodeled facility, located in Scottsdale, Arizona, will house the Provista Dx Reference Laboratory, an innovative, leading-edge CLIA accredited laboratory that is also GLP compliant.
Provista Diagnostics, Inc. develops and commercializes proprietary blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. Through the Provista Dx Reference Laboratory, the company offers a wide range of clinical diagnostic services, as well as, research contracting and biopharmaceutical testing to third parties throughout the United States. The Provista Dx Reference Laboratory, secured on a long-term lease, is both larger and superior to the site that it currently utilizes and provides a platform for further expansion of the services that can be offered. The new facility, which is both CLIA-accredited and GLP capable, is licensed in 45 states to perform human clinical testing and will offer a comprehensive menu of testing services, including custom projects.
"The move to this state-of-the-art facility clearly demonstrates the level of commitment that Provista is making to our customers and to the level of recent investments made in the company," said Dr. David Reese, President and CEO of Provista Diagnostics, Inc.
With the opening of the new facility, the company is also pleased to announce that Dr. Sherri Borman, Ph.D., HCLD/CC has joined Provista Diagnostics as its Clinical Laboratory Director. Dr. Borman, who has an extensive background in reproductive medicine and women's health, will be responsible for all clinical laboratory functions in the Provista Dx Reference Laboratory, including quality control, methodologies and certification. Dr. Borman is board certified both as a High-complexity Clinical Laboratory Director (HCLD) and a Clinical Consultant (CC) through the American Board of Bioanalysis (ABB) along with a Technical Supervisor (TS) board certification in Embryology, Andrology and Endocrinology. She has a Ph.D. in Physiological Sciences from the University of Arizona. Dr. Borman completed her NIH Post-Doctoral Fellowship at the Oregon Health & Science University in women's reproductive health. Most recently, Dr. Borman served as Laboratory Director for Kronos Science Laboratory, a position she had held since February 2009.
About Provista Diagnostics, Inc.
Provista Diagnostics, Inc., a Delaware company, develops and commercializes breakthrough, easy to administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The Company's focus is on oncology-related diagnostics where a significantly high, unmet clinical need for such testing products exists. Near term development and commercialization efforts focus on women's cancers such as breast and ovarian cancer, as well as early detection testing for lung cancer.
The Provista Diagnostics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12679
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to successfully consummate the transactions contemplated by a purchase agreement or to successfully file a registration statement with the SEC, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.